Moreover, in EGFR-mutated cancers, the non-inflamed immunosuppressive TME (high levels of Tregs and low levels of CD8+ T cells) diminishes the expression of EGFR by Tregs, leading to the development of the resistance to TKIs. The gene discussed is CD8A; the disease is cancer.